{"name":"Liquidia Technologies, Inc.","slug":"liquidia-technologies-inc","ticker":"","exchange":"","domain":"liquidiatechnologies.com","description":"Liquidia Technologies, Inc. is a biopharmaceutical company focused on the development and commercialization of novel products in the areas of respiratory disease, oncology, and rare diseases. The company leverages its proprietary PRINT® technology to design and manufacture precisely engineered particles for drug delivery.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2706981,"revenueGrowth":-62.7,"grossMargin":0,"rdSpend":40491358,"netIncome":-47583455,"cash":68842067,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"L606","genericName":"L606","slug":"l606","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"},{"name":"LIQ861 Inhaled Treprostinil","genericName":"LIQ861 Inhaled Treprostinil","slug":"liq861-inhaled-treprostinil","indication":"Pulmonary arterial hypertension (PAH)","status":"phase_3"}]}],"pipeline":[{"name":"L606","genericName":"L606","slug":"l606","phase":"phase_3","mechanism":"L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""},{"name":"LIQ861 Inhaled Treprostinil","genericName":"LIQ861 Inhaled Treprostinil","slug":"liq861-inhaled-treprostinil","phase":"phase_3","mechanism":"LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors.","indications":["Pulmonary arterial hypertension (PAH)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPQmViSGNIMXhiUFBqVE9lbTQ0cUpfRlk3R1d4N3RuTE1aTmJVNi0yMDFqNzdrWEM0Z05vZld1TGk0VkFyaWc3aDBxMnZGZWtxcjNubk0tQkdESzBLYkhFLURHbjE3REtnSWp6UTZmZEZ5Qm1saEZMNXZVb2Q0aGNVZ3lkdXJfRndpdWJfbnVFelJuT2NFMXZDVzBFQUI0UTdubXFYRFo3M2xjcFRMNnhkWVJ3SlhWSkRLeHpFcg?oc=5","date":"2026-03-25","type":"pipeline","source":"Seeking Alpha","summary":"Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha","headline":"Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOMXdqVGlEelNuQ1dLZHdhOW1WM0hUZGk5REVHU19yNkM4djVVY29ZQUJZSDJrZXpIbU9OeVY5NFJ3cm1Mc19LOWx6a1dVT0ZLdUs1Ql9nS3RDNWZwMk9TQ19qVXRNOHhVZ1RBVlluQ3lRMWFndzMwTFd3RUJsZlUwNU1PTDZDb1B5RE13WkhR?oc=5","date":"2026-03-16","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxPRWdfN3g4NnRHX1lpcmV5UDljUy0zV0xWVGhGNUNZaFM4cEtwQWtjODBlSlp2MEpvaDgtUWVDTTVRUGxxNHpaSzRhbWY5QVJ6VWNvLUxiLW1sVVczYVEtdjJkcV9Ud1NmQ09FcFBiSlJuc2RwT3ZxSkpLZTRoV3RYZmhmWlFVZ3lNNHdQMnluNENjQ3V3d2czYmpOd2JQT0hROHNuWXpRVGtoRTZZZ3ktVExiY2VBZDJnWDlaOE9sRVJpY1h4TXp4TUlhaVlMY0ctY215dDVqckwxMHVJb2ZfdmNrZmstUk5YTFVFX191UUhHVVJ0V2RqMUZQc1ctcmVXMTE1ZHhhcXBUOWI1Ung1YXBaVnZCcGpic1dKMTU1NmNRaGhqYUVabFNDY0RsS0UxN0UxNVZmT3U0UQ?oc=5","date":"2026-01-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ultragenyx Pharmaceutical (RARE) and Teva Pharmaceutical (TEVA) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ultragenyx Pharmaceutical (RARE) and Teva P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOMnY5emlaRDh5QmZzdTlHVXFqd0RyS2lDNkhMeHJ4RWp6ZWFTckV2am5VWm52ejZwcy1rOHlFMExhX0pISzZRVklaMlM2TkJ0elZFc01QemxnY1p5ZWZ5ODRZX1VRQnBQUktpU2RYaE1oM0VmTzdidDdvMWpsbzl4dkhWRzVUbk1wdzdDalZlX1JvcHZfQS1GaWRtWGZtR2cwbkx6MUI4ZWFvQ2I1aXc?oc=5","date":"2026-01-09","type":"pipeline","source":"Investing.com","summary":"Liquidia Technologies stock hits 52-week high at $36.45 - Investing.com","headline":"Liquidia Technologies stock hits 52-week high at $36.45","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQU05qbjdYS2xrbmFUY0FrdnpPRkpQMUlKbFJwdmFoN0R3WmQwbnR4T0NEcVVzbGxEeVhWMkR1TXFxY25MbkZaZlUtSjctd08za1ctcmxMYkwtSWUydkxhbjh2emduWGxtMU1rUXNaczZnaDdzMzZxZnNTd2pOYWhjamtMWTFUN2ZyZEJuNmU4RTlRa21wbnRxUHU1Nkw3RHA4dks2dWktZ1RpRXdHLTNjdmNGb2lTdlFSeEFEZmpOa00zWk45VVY2ZHgwdFNieUg4amwyeVBXNjloNzFZTjY4SkdINmVrTENIU0lXTjVjRFUxalgzeWtSVzg1X3l5UQ?oc=5","date":"2026-01-09","type":"pipeline","source":"GlobeNewswire","summary":"Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update - GlobeNewswire","headline":"Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-06","type":"pipeline","source":"simplywall.st","summary":"Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump - simplywall.st","headline":"Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5PRFlVVXVSQnpGR2g5R0ZYdHBXU0lfYmNmYlpSZHgxLW1sMW85T0NJR09mRHB0eEtFbXdpSEZENGwxSVBJZWtxZGc5YUZwa3QtWGVUS1F5NkhfWDVI?oc=5","date":"2025-08-26","type":"pipeline","source":"TradingView","summary":"LQDA Stock Price and Chart — NASDAQ:LQDA - TradingView","headline":"LQDA Stock Price and Chart — NASDAQ:LQDA","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-11","type":"earnings","source":"simplywall.st","summary":"When Can We Expect A Profit From Liquidia Corporation (NASDAQ:LQDA)? - simplywall.st","headline":"When Can We Expect A Profit From Liquidia Corporation (NASDAQ:LQDA)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOcnc0Vk1JejliX0wwZFBZb0JKVzdqUW9mc2l0QWs3eG12WlhkdjNZbGJxTmE3ak1hdy1ZX19hQ0s1aXVGc2dKUjg1LURrNlM4aENQZVZsbHF6SnJwbEpLZXIwQWZLVktFSGdQRzlNenpuVTNGNGFKSVlIdEZIZzNITVQyeXNCSkJwcVRtaG5JV0FmU0VBYjN1Yjg4LW8?oc=5","date":"2025-06-24","type":"pipeline","source":"Business North Carolina","summary":"Liquidia receives $50 million in funding related to taking drug to market - Business North Carolina","headline":"Liquidia receives $50 million in funding related to taking drug to market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPaG45QXBYOXBhOG84My1MLW9HZ0ljZlJJRUVabGdFN3UzMFE0RUZTZjlYQnFlcWpxQ2NjRlc3cUktc05TdFg4dEhyZnoxQkhsQ3Y1aHRYSnROS1BSeFFSM20xZ2NHd0lpeENBNUx6VHhiSW1sZzBOeDMtRVJrRnhqY1IzTkI5YUk4VmxZOW1iOE9EVmoxSVBN?oc=5","date":"2025-05-23","type":"pipeline","source":"The Business Journals","summary":"Drugmaker on verge of multibillion-dollar market - The Business Journals","headline":"Drugmaker on verge of multibillion-dollar market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE5GVHBCSDNUV2ZlYjhxX2liUFFMLXZLT1hkc3RZNnJXYzVGNElPUDNLSXpMQmxtNEYzN1NFcVpfYVN4QlEzYVBBSmZWdw?oc=5","date":"2024-12-05","type":"regulatory","source":"Hunterbrook","summary":"FDA Heads to Court to Defend Unprecedented Decision Protecting Lung Drug Monopoly From Liquidia Competition - Hunterbrook","headline":"FDA Heads to Court to Defend Unprecedented Decision Protecting Lung Drug Monopoly From Liquidia Competition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPdUtZa1lGT3h4dnFXUHpFNHFucWRTUUNRb3M0bW5vOUpDRkJEQmc1THdTNVp6RVV3dVlVNGNQeWhUeG1OVy12ODY4YjZKSEc0ZXdLczdiSThWN0hUQURXQlVEa2gxbnVNTmtpY0h1aE5LVzl1Sm1iVEx4bFdZQjlrTU9sd3FSaXZrTjREVXQ0WkZ6dkl1MWoyVFgzQzAwMWNvVjUxT1NpamJfTFRFZDFR?oc=5","date":"2024-08-23","type":"regulatory","source":"Axios","summary":"Liqudia sues FDA over tentative approval of its main drug - Axios","headline":"Liqudia sues FDA over tentative approval of its main drug","sentiment":"positive"},{"date":"2020-11-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2020-11-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":2706981,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":2706981,"period":"2018-12-31"},{"value":7258123,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":40491358,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-47583455,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":68842067,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}